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Prostate cancer has a low somatic mutation rate but non-coding regions remain under-
explored. We sequenced the untranslated regions (UTRs) of 72 established driver genes in
428 patients with metastatic prostate cancer and identiﬁed FOXA1 3′-UTR mutations in 12%
of patients. The mutations were predominantly insertions or deletions, covered the entire
UTR without motif enrichment, and were not detected in other cancers. FOXA1 lies in head-on
orientation with the androgen-regulated non-coding gene AL121790.1, resulting in strong
prostate lineage-speciﬁc bidirectional transcription across the FOXA1 3′-UTR. This suggests
transcriptional activity as a cause for the localized hypermutation. The indel-dominant pat-
tern of somatic mutation extends into the FOXA1 coding region, where it is shaped by clonal
selection to yield a cluster of non-frameshift indels inside the forkhead domain. Somatic
FOXA1 3′-UTR mutations may prove useful for diagnostic and screening approaches, given
their high frequency and lineage speciﬁcity.
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Prostate cancer is the second leading cause of cancer-relateddeath in men, and has a well-described somatic codinggenome deﬁned by distinct molecular subclasses and high
heterogeneity1. The mutation rate of prostate cancer is relatively
low (0.9 and 4.4 mutations per Mb in primary and metastatic
disease, respectively)2,3 and is characterized by an age-related
CG>TG mutational signature4. Conversely, chromosomal rear-
rangements (e.g., activating fusions involving ETS family tran-
scription factors) and copy number alterations (e.g., chromosome
8p loss and 8q gain) are highly prevalent2. Nevertheless, several
genes including SPOP, FOXA1, and TP53, are recurrently muta-
ted and considered to be drivers of tumorigenesis and/or
progression5.
The majority of published prostate cancer studies have lever-
aged whole-exome sequencing approaches that do not capture the
untranslated regions of protein coding genes. Although whole-
genome sequencing is beginning to reveal deep insight into the
non-coding cancer genome6–9, and has led to the discovery of
several new cancer driving mechanisms10–12, the role of reg-
ulatory region mutations in localized and metastatic prostate
cancer remains underexplored. To date, no recurrent mutations
have been identiﬁed outside coding regions in prostate cancer.
In recent years, genomic proﬁling of lethal metastatic disease in
advanced cancer patients has become more practical through the
use of liquid biopsies. Cell-free circulating tumor DNA (ctDNA)
is highly abundant in the plasma of metastatic castration-resistant
prostate cancer (mCRPC) patients13–15. We have demonstrated
that somatic mutation and copy number proﬁles for prostate
cancer driver genes are strongly concordant between matched
ctDNA and metastatic tissue specimens from mCRPC patients16.
In a recent study of ctDNA-positive samples from 115 mCRPC
patients we observed mutations within the UTRs of several
prostate cancer driver genes, including FOXA1 and the androgen
receptor (AR)15. We hypothesized that some prostate cancer
associated genes may exhibit an elevated UTR mutation rate. In
this study, we report mutation frequencies in the UTRs of 72
known prostate cancer driver genes in 428 men with mCRPC,
and identify an indel-dominated pattern of somatic mutation
encompassing the entire FOXA1 3′-UTR and C-terminal.
Results
Low mutation rate in UTRs of prostate cancer driver genes. We
performed targeted sequencing across all exons of 72 prostate
cancer driver genes in 712 plasma cell-free DNA (cfDNA) sam-
ples from 428 mCRPC patients (Supplementary Data 1). Circu-
lating tumor DNA fraction was above 2% of total cfDNA in 439/
712 (62%) samples (290/428 patients, 68%). Samples with ctDNA
fractions below 2% were not included in further analyses due to
reduced sensitivity for mutation detection15. Across the 72 genes
in our panel, we achieved ≥200× sequencing depth for 94% and
70% of positions within annotated 3′- and 5′-UTRs, respectively
(Fig. 1a, Supplementary Fig. 1, Supplementary Data 2 and 3).
Median sequencing depth inside targeted regions was 751× (IQR
616× to 899×). At this sequencing depth, we achieve >90% sen-
sitivity for detecting somatic mutations at allele fractions above
3.5%, as previously shown15.
A total of 1945 somatic mutations were detected in the 439
ctDNA-positive samples (Supplementary Data 1). Of these 1945
mutations, 992 (51%) were in coding regions, 271 (14%) were in
UTRs, and 682 (35%) were in introns or intergenic regions. The
average somatic mutation rate in UTRs was signiﬁcantly lower
than for coding regions (4.0 vs 10.5, p < 10−16, binomial test) and
was similar between 5′- and 3′-UTRs (Fig. 1b), but varied
between genes. The high mutation rate in coding regions was
expected since our panel targets recurrently mutated prostate
cancer genes. The fraction of substitution vs indel mutations was
similar in UTRs and coding regions (73% vs 68% substitutions,
p= 0.095, Fisher’s exact test). In line with large published
prostate cancer cohorts2,3,15, the most commonly mutated genes
were TP53, AR, FOXA1, APC, KMT2D, SPOP, and PTEN,
primarily driven by missense and truncating mutations inside the
coding region (Fig. 1c).
The FOXA1 3′-UTR displays a high rate of indel mutations.
The highest number of non-coding mutations was observed in
the FOXA1 3′-UTR, which harbored 37 somatic mutations in 34/
290 (12%) mCRPC patients (Fig. 1c, Supplementary Data 4). The
androgen receptor (AR) 3′-UTR harbored the second highest
number of non-coding mutations, but this was driven by 3
patients that carried AR gene ampliﬁcation together with AR 3′-
UTR hypermutation (Supplementary Data 4). No other UTR in
our panel was mutated in more than 10 patients, suggesting that
UTR somatic mutation is not a common mechanism of driver
gene deregulation in prostate cancer. The FOXA1 3′-UTR is 1814
bp in length, slightly larger than the median of other 3′-UTRs in
our panel (1344 bp, range 0–10.2 kb). However, when controlling
for UTR length, FOXA1 still displayed three times as many
mutations per kb than any other 3′-UTR (Fig. 1d). Among the 71
other genes included in our panel, a total of 141 somatic 3′-UTR
mutations were detected, only 19 (13%) of which were indels. In
contrast, FOXA1 3′-UTR mutations were predominantly dele-
tions (62%) or insertions (19%) (81% vs 13% indels, p= 1.6e−14,
Fisher’s exact test) (Fig. 1d, Supplementary Data 4). The FOXA1
3′-UTR deletions ranged in size between 1 and 89 bp (median 8
bp), and insertions between 1 and 99 bp (median 18 bp). With the
exception of a 3 bp deletion inside an AACAAC microsatellite
(identiﬁed in both PC-225 and PC-074), all 3′-UTR mutations
were unique to a single patient. Mutations were heterozygous in
all evaluable cases. Sanger sequencing conﬁrmed the presence of
high allelic frequency FOXA1 3′-UTR indel mutations in 5/5
cfDNA samples that were tested (Supplementary Fig. 2). As
further validation, we obtained diagnostic tumor tissue from two
patients (PC-225 and PC-235) whose cfDNA showed FOXA1 3′-
UTR mutations. In both cases the same mutations were detected
in tissue by targeted and Sanger sequencing (Supplementary
Figs. 2−4, Supplementary Data 5). Finally, to conﬁrm FOXA1 3′-
UTR mutations in whole-genome sequencing data, we studied a
published cohort of 52 metastatic tissue samples from 10 prostate
cancer patients17, and identiﬁed FOXA1 3′-UTR mutations in
two patients. The mutations were present in all metastatic tissue
from these patients (Supplementary Data 5, Supplementary
Figs. 5, 6).
The indel pattern extends into the FOXA1 coding region. The
FOXA1 coding region is mutated in 5–10% of prostate
tumors2,3,5,18, with over half of reported mutations falling within
or near the forkhead domain (Fig. 1e). These mutations are
presumed to confer a selective advantage via altered DNA bind-
ing speciﬁcity19. However, occasional indel mutations have also
been reported downstream of the forkhead domain, in the C-
terminal transactivation domain2. The impact of these (often
truncating) mutations is unclear. In our cohort, 34/290 patients
(12%) harbored mutations within the FOXA1 coding region,
including 23 mutations that fell within or near the forkhead
domain, consistent with published studies (Fig. 1e)2,5. In total,
57/290 (20%) patients in our cohort harbored at least one FOXA1
coding region or UTR mutation.
Overlapping our mutation analysis with published coding
region data revealed a clear pattern of indel mutations affecting
both the 3′-UTR and the coding region as far as the forkhead
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domain (Fig. 1e). Mutation density was slightly higher at the 3′
end of the FOXA1 3′-UTR, and tapered off towards 5′ end and
the coding region (Fig. 2a). Very few frameshift indels were
observed in amino acids 1–272, only inframe events, suggesting
negative selective pressure for alterations that truncate or
inactivate the forkhead domain. Base composition within a 20
bp neighborhood around the breakpoints was consistent with
the 3′-UTR average (Fig. 2b), and we did not identify any
recurrent sequence motifs adjacent to the indel breakpoints
(Fig. 2c). Of the 22 deletions inside the FOXA1 3′-UTR, 5
involved deletion of one repeat from a tandem repeat sequence
(e.g. AATAATAAT->AATAAT deletion in PC-235), while 6/7
insertions inside the 3′-UTR were short-tandem duplications
(Supplementary Data 6). Phylogenetic conservation scores
around somatic mutations were in line with the 3′-UTR
average (average 0.73 vs 0.65, p= 0.66, rank-sum test) (Fig. 2a).
Taken together, these results suggest that the mutation process
affects the entire 3′-UTR without enrichment at speciﬁc
regions.
FOXA1 3′-UTR mutations were detected more frequently in
patients that also carried mutations in the FOXA1 coding region
(32% vs 8%, p= 0.0007, Fisher’s exact test). We found no
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Fig. 1 Somatic mutation rates in the untranslated regions of prostate cancer driver genes. a Comparison of untranslated region coverage between our 72-
gene panel and the Agilent SureSelect Human All Exon panel used by the Cancer Genome Atlas prostate adenocarcinoma (TCGA PRAD) working group.
Coverage threshold was 200× for the 72-gene panel (sufﬁcient for mutation detection from ∼10% ctDNA sample) and 50× for the Agilent SureSelect
Human All Exon panel (sufﬁcient for mutation detection from tissue with ∼30% cancer fraction). Incomplete coverage of BRAF, GNAS, and PIK3CB UTRs
was due to differences in annotated UTR length between RefSeq (used for panel design) and Ensembl (used in this study). b Comparison of somatic
mutation rate in the coding vs untranslated regions covered by our 72-gene panel. Mutation rate was deﬁned as the total number of somatic mutations,
divided by the number of genomic positions with >200× coverage (in megabases), divided by the number of cfDNA samples with ctDNA >2%. c Bar plot
showing 15 genes with the highest number of somatic mutations, broken down by mutation type and region. Percentage of samples carrying one of the
included mutation types is shown on the right. d Bar plot showing 15 genes with the highest 3′-UTR mutation rate. Mutation count was normalized by
number of ctDNA-positive samples (n= 439) and 3′-UTR length in megabases. Percentage of samples carrying a 3′-UTR mutation is shown on the right.
e Distribution of somatic mutations along the FOXA1 exonic regions, in our cohort (top) and in published whole-exome sequencing cohorts (bottom). For
consistency with the coding region, indels in the 3′-UTR were also colored based on length, although they cannot result in frameshifts. Gray silhouettes
indicate sequencing coverage
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association between FOXA1 3′-UTR mutations and genomic
alterations in other recurrently mutated genes (Supplementary
Fig. 7).
FOXA1 UTR mutations are found in early stage prostate
cancer. Mutations that arise late in cancer development are
sometimes only present in a subset of ctDNA-releasing cancer
cells, and can exhibit a lower mutant allele fraction in cfDNA. In
the 72 genes captured by our panel, ctDNA%-corrected mutant
allele fractions were generally lower in 3′-UTRs than in coding
regions (0.34 vs 0.54, p= 1.1e−19, ranksum test), consistent with
coding region mutations being subject to positive selection and
loss-of-heterozygosity (Fig. 2d). The allele fractions of FOXA1 3′-
UTR mutations, after correction for ctDNA%, were not sig-
niﬁcantly higher or lower than allele fractions of 3′-UTR muta-
tions in other genes (p= 0.95) (Fig. 2d). The same was true of
FOXA1 coding region mutations (p= 0.09) (Fig. 2d). This sug-
gests that FOXA1 3′-UTR mutations are not simply a late or
predominantly subclonal event in prostate cancer. To investigate
further, we examined nine mCRPC patients with FOXA1 3′-UTR
mutations who provided multiple ctDNA-positive (ctDNA > 5%)
specimens over their clinical time course. In seven of these
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patients, the same FOXA1 3′-UTR mutation was detected at all
timepoints (Fig. 2e). In two patients (PC-030 and PC-383), the 3′-
UTR mutation harboring clone rose to prominence late in their
clinical time course, based on complete absence of supporting
reads in earlier timepoints (Fig. 2e, Supplementary Fig. 8). Evi-
dence for loss of FOXA1 3′-UTR mutation from ctDNA over time
was not observed in any patients.
Secondly, we interrogated a published dataset (generated with
the identical 72 gene panel) of matched diagnostic tissue biopsy
and radical prostatectomy specimens from localized prostate
cancer20. In this dataset, there were 33 patients with at least one
somatic mutation within the 72 gene panel, and 3/33 (9%)
harbored FOXA1 3′-UTR indel mutations. All three patients were
positive for the same FOXA1 3′-UTR mutation in their diagnostic
needle biopsy and in their radical prostatectomy specimen
collected 4–6 months later (Supplementary Data 5). Together,
these results suggest that FOXA1 3′-UTR indel mutations are
prevalent in both primary and metastatic disease but do not show
enrichment consistent with selection in advanced disease.
Consistent with a passenger role in prostate cancer cells,
among the 202 mCRPC patients in our cohort with long term
follow-up data15, presence of FOXA1 3′-UTR alterations did
not inﬂuence time to progression on ﬁrst-line abiraterone or
enzalutamide therapy (5.6 vs 5.5 months, hazard ratio= 1.03,
95% CI 0.57–1.87, p= 0.92, univariate Cox proportional
hazards model) or overall survival from mCRPC treatment
initiation (16.6 vs 18.2 months, hazard ratio= 1.46, 95% CI
0.78–2.74, p= 0.24) (Supplementary Fig. 9, Supplementary
Data 7).
FOXA1 UTR indels are not detected in other cancers. FOXA1 is
only expressed in some adult tissues, with the highest levels
observed in prostate tissue (Supplementary Fig. 10). Accordingly,
prostate cancer exhibits higher FOXA1 expression than other
malignancies (Fig. 3a). Breast and bladder cancer express the second
and third highest levels of FOXA1, respectively. Using a published
bladder cancer focused approach21, we assessed the FOXA1 muta-
tion rate in 71 advanced bladder cancer patients. Although the
bladder cancer panel achieved high sequencing depth throughout
the FOXA1 3′-UTR (Supplementary Fig. 11), only one mutation
(a base substitution) was identiﬁed among the 53/71 patients with
sufﬁcient ctDNA or cancer tissue cellularity (p= 0.04 for compar-
ison with 33/290 in prostate cancer, Fisher’s exact test). Although
we could not directly assess the FOXA1 3′-UTR in breast cancer
samples, we note that somatic indels in the FOXA1 coding region
are signiﬁcantly less frequent in breast cancer than prostate cancer
(5/982 in TCGA breast invasive carcinomas vs 15/499 in TCGA
prostate adenocarcinomas, p= 0.0002, Fisher’s exact test). Together
these data suggest that bladder and breast cancer do not harbor the
distinctive indel signature observed 3′ of the FOXA1 forkhead
domain in prostate cancer.
FOXA1 UTR is subject to strong bidirectional transcription.
Recurrent translocation of the ETS family gene ETV1 to a region
downstream of FOXA1 on chromosome 14 has been observed in
prostate cancer patients and cell lines22,23. Although the MIPOL1
loci (the adjacent coding gene) is often described as the insertion
point for these ETV1 translocations, the 38 kb region between
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MIPOL1 and FOXA1 harbors the non-coding gene AL121790.1
(also known as ENSG00000258414 and EST14) that has been
reported to exhibit androgen-regulated and prostate-speciﬁc
expression22. Fusion of AL121790.1 with ETV1 is consistent
with other ETS rearrangements in prostate cancer, which typi-
cally involve an AR driven promoter1. Analysis of RNA
sequencing data from 33 cancer types revealed that AL121790.1
expression is strongly correlated with FOXA1 expression
(Spearman correlation= 0.84) (Fig. 3b). Expression of
AL121790.1 was highest in prostate cancer, 8-fold higher than in
breast cancer and 30-fold higher than in any of the other 31
cancer types. We also conﬁrmed the correlation between
AL121790.1 and AR activity (Fig. 3c) and additionally performed
AR chromatin immunoprecipitation sequencing (ChIP-seq) on
the prostate cancer cell line LNCaP treated with R1881 (a syn-
thetic testosterone analog). We identiﬁed an AR binding site
within 2.8 kb of the AL121790.1 promoter, supported by the
presence of a canonical androgen responsive element motif24
(Fig. 3d). Interestingly, in the TCGA prostate adenocarcinoma
dataset2, the two patients with fusions juxtaposing the MIPOL1
locus with ETV1 had RNA-level fusion junctions that matched
exactly with the end of the ﬁrst annotated exon of AL121790.1
(Fig. 3d)—suggesting that this AR-regulated non-coding gene is a
common 5′ fusion partner in ETV1 gene rearrangements, where it
drives ETV1 overexpression through its highly active promoter.
To understand whether the mutation process extends down-
stream of the FOXA1 3′-UTR, we analyzed whole-genome
sequencing data from the aforementioned cohort 10 metastatic
prostate cancer patients and identiﬁed ﬁve somatic mutations in
the 25 kb region between AL121790.1 TSS and FOXA1, and no
mutations in the non-transcribed 11 kb region between MIPOL1
and the AL121790.1 (Supplementary Data 5). This supports the
hypothesis that the high mutation burden in this region is
associated with transcription.
To further investigate a potential relationship between
AL121790.1 expression, FOXA1 expression, and FOXA1 3′-UTR
mutations, we studied published strand-speciﬁc RNA sequencing
data from prostate adenocarcinoma tissue25. AL121790.1 is in
head-on orientation with FOXA1, and its RNA products overlap
with the FOXA1 3′-UTR in prostate cancer cells (Fig. 3d).
Published strand-speciﬁc RNA sequencing data from breast26 and
bladder cancer (SRA project SRP103878) revealed no evidence for
transcriptional overlap at the FOXA1 3′-UTR, due to low
AL121790.1 expression (Supplementary Fig. 12). Interestingly,
the entire region spanning AL121790.1 and FOXA1 has been
identiﬁed as a super-enhancer (dbSUPER:SE_33900) in various
human cell types, with a topologically associated domain
encompassing both AL121790.1 and FOXA1, suggesting shared
regulation. Ultimately, the strong bidirectional transcription
reported here raises the possibility of head-on transcriptional
collisions, transcriptional stalling, and replication-transcription
collisions27, which may increase the potential for DNA damage in
this region28.
Discussion
Prostate cancer has a low somatic mutation rate in coding
regions, and our data suggest this extends to the UTRs of known
prostate cancer driver genes, with the notable exception of
FOXA1. The previously unrecognized FOXA1 3′-UTR mutations
reported here, together with established forkhead domain muta-
tions, implicate FOXA1 as the third most commonly mutated
gene in advanced prostate cancer, after TP53 and AR. However,
although FOXA1 forkhead domain mutations contribute to
prostate cancer pathogenesis, the indel mutations we identiﬁed
within the 3′-UTR and C-terminus appear to be passenger events.
We did not observe evidence for their selection at different stages
of disease progression, nor were they localized to any particular
hotspots downstream of the forkhead domain.
The UTRs of coding genes are not captured in standard whole-
exome sequencing protocols, including those used in TCGA
efforts. Furthermore, although hundreds of localized prostate
tumors have been subjected to whole genome sequencing29, no
study has searched for UTRs with an elevated mutation rate to
our knowledge, and the typical 15–30X whole-genome sequen-
cing depth can pose a challenge for the discovery of novel
mutations. Support for FOXA1 3′-UTR localized hypermutation
in prostate cancer can be drawn from the following: (1) in all but
one example the 3′-UTR mutations were unique to individual
patients, yet where patients had multiple plasma or tissue col-
lections performed, the same mutations were observed; (2)
mutations were detected at similar frequencies in our plasma
cfDNA and tumor tissue cohorts; (3) applying our capture-based
targeted sequencing approach to plasma cfDNA from patients
with metastatic bladder cancer yielded no FOXA1 3′-UTR indel
mutations; (4) Sanger sequencing of 3′-UTR mutations with high
variant allele frequency conﬁrmed their presence in all tested
samples; and (5) analysis of independent published whole-
genome sequencing data from metastatic prostate cancer revealed
FOXA1 3′-UTR mutations in 2/10 patients.
Patients with FOXA1 coding region mutations had a sig-
niﬁcantly higher likelihood of carrying FOXA1 3′-UTR muta-
tions, suggesting that the probability of accruing any mutation in
this region varies between patients. The connection between
FOXA1 coding region and UTR mutations, together with the
unusually high rate of non-frameshift indels in the FOXA1
forkhead domain, suggests that prostate cancer driver mutations
in this domain arise due to a combination of a localized mutation
process and clonal selection.
A recent study demonstrated that certain highly expressed and
lineage-speciﬁc genes in lung, liver, stomach, and thyroid cancers
harbor 3′-UTR indel hotspots8. In some genes, this apparent
localized hypermutation extended beyond the 3′-UTR into the
intergenic region. The mechanistic etiology of the hypermutation
signature was unclear, but similar to the FOXA1 indel mutations
reported here, the 3′-UTR indel hotspots did not appear to be
under selective pressure. FOXA1 expression is lineage restricted,
and very high in prostate cancer. However, FOXA1 is also tran-
scribed in head-to-head orientation with another highly expres-
sed and lineage-speciﬁc gene, AL121790.1. Given that AL121790.1
is AR regulated, the combination of high FOXA1 and AL121790.1
expression (overlapping within the FOXA1 exonic region) is likely
unique to the prostate lineage. It is well established that collisions
between DNA replication and transcription machinery can trig-
ger mutations28. Indeed, high levels of transcription have been
associated with genomic damage30. When RNA polymerase II
complexes collide head-to-head, they cannot bypass each other,
transcription halts, and the complexes require removal from
DNA via ubiquitination-directed proteolysis27. This can increase
the number of stalled RNA polymerase complexes in the locus27,
facilitating collisions with DNA replication. Unfortunately, our
current data do not allow us to disambiguate the relative con-
tributions of bidirectional transcription, high cumulative tran-
scription, or other mechanisms towards the FOXA1 mutation
process. We also cannot rule out the possibility that FOXA1
and AL121790.1 are expressed in a coordinated manner so
that the genes are never simultaneously transcribed from
the same chromosome copy. Future studies should assess
whether lineage-restricted genes in other cancers lie in
head-to-head orientation, and whether regions subjected to high
levels of bidirectional transcription exhibit elevated indel
mutation rates.
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Liquid biopsy strategies such as the one employed here rely on
the detection of somatic mutations to conﬁrm the presence and
fraction of tumor DNA in the circulation. Additionally, assays
applied in the diagnostic setting or for disease recurrence mon-
itoring are augmented by detection of somatic variants (or com-
bination of variants) that inform on the cancer type. For example,
while TP53 mutations can be found in many different cancers,
SPOP MATH domain mutations are restricted to prostate and
endometrial cancers. In cancers with low mutation rates (such as
prostate cancer), gene panels must span a large genomic territory to
increase the probability of detecting informative somatic variants.
We posit that the FOXA1 3′-UTR represents a useful region for
liquid biopsy gene panels, since any panel spanning this region will
capture ~20% of patients and the detection of UTR indels can help
conﬁrm prostate cancer origin for the ctDNA. Furthermore, the
frequency of FOXA1 locus mutations reported in this study may
actually be underestimated due to reduced mutation calling sensi-
tivity in samples with <5% ctDNA15.
In addition to recurrent FOXA1 forkhead domain mutations,
the 14q21.1 region is also a recurrent partner in ETV1-activating
structural rearrangements in prostate cancer. In TCGA prostate
adenocarcinoma samples, these fusions juxtapose the ﬁrst exon of
AL121790.1 with ETV1, turning ETV1 into an AR-regulated gene
with high expression, as has been demonstrated in earlier
studies22,23. This implicates the long non-coding gene
AL121790.1 as a facilitator in two distinct prostate cancer driving
mechanisms (FOXA1 mutations and ETV1 fusions).
Methods
Study design and patients. Plasma cell free DNA samples from 428 mCRPC
patients and 71 bladder cancer patients were sequenced as part of the genitourinary
cancers liquid biopsy biobank program at the Vancouver Prostate Center, Uni-
versity of British Columbia and the British Columbia Cancer Agency. Approval for
collection and genomic proﬁling of patient samples was granted by the University
of British Columbia Research Ethics Board (certiﬁcate numbers H18-00944, H14-
00738, H16-00934, and H09-01628). The study was conducted in accordance with
the Declaration of Helsinki, and written informed consent was obtained from all
participants prior to enrollment.
Target capture and sequencing. A custom NimbleGen SeqCap EZ Choice target
capture panel was used to capture the coding regions of 72 genes (Supplementary
Data 1). For each sample, 10–100 ng of DNA was used for library preparation.
White blood cell gDNA samples were sheared into 180 bp fragments with a Covaris
focused-ultrasonicator. A-tailing, end repair, Illumina-compatible adapter ligation
and PCR ampliﬁcation (between 12 and 17 cycles) was performed. Library quan-
tiﬁcation was carried out with the NanoDrop spectrophotometer, and each library
was run on an ethidium bromide gel to conﬁrm success. Up to 25 puriﬁed sample
libraries at a time were multiplexed to obtain single pools with a combined mass of
1 μg, allowing a minimum 40 ng input for each sample library. These pools were
hybridized to the capture panel for a minimum of 16 h at 47 °C. The subsequent
wash, recovery, and ampliﬁcation of the captured regions was performed according
to the NimbleGen SeqCap EZ system protocols. Final libraries were puriﬁed with
Agencourt AMPure beads and quantitated using either the KAPA qPCR kit, or the
Qubit 2.0 Fluorometer (Life Technologies) and Qubit dsDNA HS Assay Kit. Pools
were diluted to 20 pM, and were sequenced on Illumina MiSeq (V3 600 cycle kit)
or HiSeq 2500 (V4 250 cycle kit) machines.
Sequence alignment and quality control. Paired-end reads were aligned against
the hg38 reference genome using Bowtie-2.3.031. Optical and PCR duplicates were
removed using samblaster-0.1.2432. Adapters were trimmed in paired mode using
cutadapt-1.1133. Low-quality read tails (smoothed baseq < 30) were trimmed using
an in-house algorithm. cfDNA/WBC sample pairings were veriﬁed based on SNP
genotypes.
Analysis of somatic mutations. Somatic mutations were called in cfDNA samples
by searching for variants with an alternate allele fraction of at least 1%, and at least
10 supporting reads. Additionally, the allele fraction was required to be 25 times
higher than the background error rate (i.e., the average allele fraction across all
WBC samples), and 3 times higher than the allele fraction in the paired WBC
sample. The paired WBC sample was required to have at least 20 reads covering the
site. Protein-level consequences of variants were predicted using ANNOVAR34.
Somatic mutation analysis for bladder cancer cfDNA samples was carried out using
the same methodology.
To search for large indels, unaligned reads from each sample were split into two
30 bp anchors (from the 5′ and 3′ ends of the read) and aligned to the hg38
genome. Discordant anchor pairs were grouped by position and breakpoint
signature. Duplicate reads arising from the same original cfDNA fragment were
discarded based on read IDs and read start positions. Long indel candidates
supported by three or more unique cfDNA fragments were manually curated using
IGV and BLAT. Indels longer than 500 bp were excluded from analysis to maintain
focus on localized mutational processes.
For each of the 72 genes captured by our panel, we determined the coordinates
of its 5′ and 3′ untranslated regions based on annotations from Ensembl 90. RNA
sequencing data from TCGA prostate adenocarcinoma samples was used to
determine the predominantly expressed splice variant of each gene. UTR mutations
were not allowed to overlap any annotated CDS for the gene in any of its splice
variants.
Analysis of gene expression across cancer types. RNA sequencing data for 165
cancer samples encompassing 33 cancer types (5 cancer samples from each cancer
type) was downloaded from NCI Genomic Data Commons (GDC) Data Portal in
BAM format. RNA sequencing reads aligning to FOXA1 neighbor genes (FOXA1,
AL121790.1, MIPOL1) and seven AR-regulated genes (TMPRSS2, KLK2, KLK3,
SLC45A3, FKBP5, NKX3-1, ACSL3) were counted using Subread35 and converted
to RPKM units by normalizing with transcript length and library size. AR activity
score was calculated as the median expression of the seven AR-regulated genes.
Code availability. Computer code for analyses performed in this study is available
in the Github repository https://github.com/annalam/foxa1-utr-manuscript-code.
Code for structural rearrangement analysis is available in Github repository https://
github.com/annalam/breakfast. Code for FASTQ/BAM ﬁle manipulation is avail-
able in Github repository https://github.com/annalam/seqkit.
Data availability. De-identiﬁed sequencing data was deposited to the European
Genome-phenome Archive (EGA) under study identiﬁer EGAS00001003113 and is
available under standard EGA controlled release. Patients signed informed consent
for their blood specimens to be used for future cancer research purposes.
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